Marjo Jag de Ronde-Tillmans

Marjo Jag de Ronde-Tillmans

Auto-generated profile, based on publicly available information

Marjo Jag de Ronde-Tillmans

Department of Cardiology, Erasmus MC, University Medical Center Rotterdam , Rotterdam

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2021 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Open access
PDF file
MWMaarten P. van Wiechen
Maarten P. van Wiechen
HKHerbert Kroon
Herbert Kroon
THThijmen W. Hokken
Thijmen W. Hokken
JOJoris F. Ooms
Joris F. Ooms
MRMarjo J. de Ronde‐Tillmans
Marjo J. de Ronde‐Tillmans
NMNicolas M. Van Mieghem
Nicolas M. Van Mieghem
Background: The MANTA vascular closure device (VCD) is dedicated to large bore access closure and associated with favorable results in selected study populations. Anatomical predictors for access site complications are lacking.Aim: To evaluate MANTA in a real‐world population and identify predictors for vascular complications.Methods: All patients undergoing transfemoral transcatheter aortic valve replacement (TAVR) between January 2016 and May 2020 with MANTA closure were included. Baseline characteristics were collected, pre‐procedural computed tomography and post‐deployment femoral angiograms were analyzed for anatomical differences. The primary endpoint was a composite of access site related major and minor vascular complications at 30 days follow‐up according to the VARC‐2 definitions. Secondary endpoints included bleeding, time to hemostasis, procedural length and incomplete arteriotomy closure or arterial occlusion by angiography. A Cox proportional hazards model was used to compare all‐cause mortality for patients with and without an access site complication.Results: The 512 patients underwent TAVR with MANTA access closure. Median age was 80 (IQR 75–85), 53% was male, median BMI was 26.4 kg/m2 (IQR 23.4–29.7). Access site related major‐ or minor vascular complication occurred in 20 (4%) and 23 (4%) of patients respectively. Median time to hemostasis was 42 s (IQR 28–98). Post deployment angiogram showed an occlusion in 24 patients (5%), incomplete closure in 60 patients (12%) or both in three patients (1%). Of these 87 patients, 36 (41%) had a vascular complication. Femoral artery diameter (OR 0.70 [0.53–0.93]), low‐ (OR 3.47 [1.21–10.00]) and high (OR 2.43 [1.16–5.10]) arteriotomies were independent predictors for vascular complications.Conclusion: In this contemporary TAVR population, access‐site related complications occurred in 8% of patients and were mainly due to percutaneous closure device failure. Small artery diameter and off‐target punctures were independent predictors.

1 August 2019 in Clinical Interventions in Aging
Verified
Journal Article
Open access
JGJeannette Goudzwaard
Jeannette Goudzwaard
EDEleonora Disegna
Eleonora Disegna
MRMarjo Jag de Ronde-Tillmans
Marjo Jag de Ronde-Tillmans
MLMattie J Lenzen
Mattie J Lenzen
PJPeter Pt de Jaegere
Peter Pt de Jaegere
FMFrancesco Mattace-Raso
Francesco Mattace-Raso
Both aortic valve stenosis and aortic stiffness are moderators of arterio ventricular coupling and independent predictors of cardiovascular morbidity and mortality. Studies on the effect of transcatheter aortic valve implantation (TAVI) on aortic functional properties are limited. We performed a study to investigate the possible short-term changes in aortic stiffness and other aortic functional properties after TAVI in older patients. TAVI Care&Cure is an observational ongoing study including consecutive patients undergoing a TAVI procedure. Central and peripheral hemodynamic measurements were measured non invasively 1 day before (T-1) and 1 day after (T+1) TAVI using a validated oscillometric method using a brachial cuff (Mobil-O-Graph). 40 patients were included. Mean aortic valve area at baseline was 0.76±0.24 cm2. Indices of severity of aortic valve stenosis improved significantly. Systolic blood pressure (SBP) dropped by 8.5%, from 130.3±22.9 mmHg to 119.5±15.8 mmHg (p=0.005). Diastolic blood pressure (DBP) dropped by 13.1% from 74.8±14.5 mmHg to 65.0±11.3 mmHg (p<0.001). The arterial pulse wave velocity (aPWV) decreased from 12.05±1.99 m/s to 11.6±1.56 m/s (p=0.006). Patients with high aPWV at baseline showed a significantly larger reduction in SBP in comparison to patients with low aPWV: - 20.3 mmHg (-14.1%) vs - 3.1 mmHg (-2.6%), respectively (p=0.033). The same trend was found for the DBP: -16.2 (-20.4%) vs -4.5 mmHg (-6.3%) for high vs low aPWV at baseline (p=0.037). We found short-term changes in blood pressure and aortic stiffness after TAVI. The amplitude of the changes was the largest in patients with elevated aortic stiffness at baseline.

27 November 2021 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Open access
PDF file
THThijmen W. Hokken
Thijmen W. Hokken
MRMarjo de Ronde
Marjo de Ronde
QWQuinten Wolff
Quinten Wolff
TSThom Schermers
Thom Schermers
JOJoris F. Ooms
Joris F. Ooms
NMNicolas M. Van Mieghem
Nicolas M. Van Mieghem
Objectives: To study the safety and feasibility of a restrictive temporary‐RV‐pacemaker use and to evaluate the need for temporary pacemaker insertion for failed left ventricular (LV) pacing ability (no ventricular capture) or occurrence of high‐degree AV‐blocks mandating continuous pacing.Background: Ventricular pacing remains an essential part of contemporary transcatheter aortic valve implantation (TAVI). A temporary‐right‐ventricle (RV)‐pacemaker lead is the standard approach for transient pacing during TAVI but requires central venous access.Methods: An observational registry including 672 patients who underwent TAVI between June 2018 and December 2020. Patients received pacing on the wire when necessary, unless there was a high‐anticipated risk for conduction disturbances post‐TAVI, based on the baseline‐ECG. The follow‐up period was 30 days.Results: A temporary‐RV‐pacemaker lead (RVP‐cohort) was inserted in 45 patients, pacing on the wire (LVP‐cohort) in 488 patients, and no pacing (NoP‐cohort) in 139 patients. A bailout temporary pacemaker was implanted in 14 patients (10.1%) in the NoP‐cohort and in 24 patients (4.9%) in the LVP‐cohort. One patient in the LVP‐cohort needed an RV‐pacemaker for incomplete ventricular capture. Procedure time was significantly longer in the RVP‐cohort (68 min [IQR 52–88.] vs. 55 min [IQR 44–72] in NoP‐cohort and 55 min [IQR 43–71] in the LVP‐cohort [p < 0.005]). Procedural high‐degree AV‐block occurred most often in the RVP‐cohort (45% vs. 14% in the LVP and 16% in the NoP‐cohort [p ≤ 0.001]). Need for new PPI occurred in 47% in the RVP‐cohort, versus 20% in the NoP‐cohort and 11% in the LVP‐cohort (p ≤ 0.001).Conclusion: A restricted RV‐pacemaker strategy is safe and shortens procedure time. The majority of TAVI‐procedures do not require a temporary‐RV‐pacemaker.

1 May 2018 in JACC: Cardiovascular Imaging
Verified
Journal Article
Closed access
NFNahid El Faquir
Nahid El Faquir
BRBen Ren
Ben Ren
MFMarguerite Faure
Marguerite Faure
MRMarjo de Ronde
Marjo de Ronde
PGPatrick Geeve
Patrick Geeve
NMNicolas M. Van Mieghem
Nicolas M. Van Mieghem

28 July 2021 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Closed access
PDF file
MWMaarten P van Wiechen
Maarten P van Wiechen
MFMarguerite E Faure
Marguerite E Faure
THThijmen W Hokken
Thijmen W Hokken
JOJoris F Ooms
Joris F Ooms
MRMarjo J de Ronde-Tillmans
Marjo J de Ronde-Tillmans
NMNicolas M Van Mieghem
Nicolas M Van Mieghem
To elucidate the frequency and clinical impact of left atrial appendage thrombus (LAAT) in patients set for transcatheter aortic valve implantation (TAVI). All patients undergoing TAVI between January 2014 and June 2020 with analysable multislice computed tomography (MSCT) for LAAT were included. Baseline and procedural characteristics were collected, pre-procedural MSCT’s were retrospectively analysed for LAAT presence. The primary endpoint was defined as the cumulative incidence of any cerebrovascular event (stroke or transient ischaemic attack) within the first year after TAVI. A Cox proportional hazards model was used to identify predictors. A total of 1050 cases had analysable MSCT. Median age was 80 [interquartile range (IQR) 74–84], median Society of Thoracic Surgeons’ Predicted Risk Of Mortality (STS-PROM) was 3.4% (IQR 2.3–5.5). Thirty-six percent were on oral anticoagulant therapy for atrial fibrillation (AF). LAAT was present in 48 (4.6%) of cases. Patients with LAAT were at higher operative risk [STS-PROM: 4.9% (2.9–7.1) vs. 3.4% (2.3–5.5), P = 0.01], had worse systolic left ventricular function [EF 52% (35–60) vs. 55% (45–65), P = 0.01] and more permanent pacemakers at baseline (35% vs. 10%, P < 0.01). All patients with LAAT had a history of AF and patients with LAAT were more often on vitamin K antagonist-treatment than patients without LAAT [43/47 (91%) vs. 232/329 (71%), P < 0.01]. LAAT [hazard ratio (HR) 2.94 (1.39–6.22), P < 0.01] and the implantation of more than one valve [HR 4.52 (1.79–11.25), P < 0.01] were independent predictors for cerebrovascular events. Patients with MSCT-identified LAAT were at higher risk for cerebrovascular events during the first year after TAVI. Multislice computed tomography detected left atrial appendage thrombus is an independent predictor for cerebrovascular events within the first year after transcatheter aortic valve implantation. Multislice computed tomography detected left atrial appendage thrombus is an independent predictor for cerebrovascular events within the first year after transcatheter aortic valve implantation.

1 January 2026 in European Heart Journal - Valvular and Structural Heart Disease
Verified
Journal Article
Open access
PDF file
SLSandra B Lauck
Sandra B Lauck
BKBettina Højberg Kirk
Bettina Højberg Kirk
GMGemma McCalmont
Gemma McCalmont
DFDerk Frank
Derk Frank
MRMarjo de Ronde-Tilmans
Marjo de Ronde-Tilmans
DMDouglas F Muir
Douglas F Muir
Background: Transcatheter options are increasingly available for the treatment of valvular heart disease. The role of the clinical valve co-ordinator is ideally positioned to improve access to care, quality of outcomes, and patient experiences, contribute to efficiencies, and support the growing number of heart valve centres. International societies and guidelines recommend the inclusion of the clinical valve co-ordinator in multidisciplinary Heart Teams to support patients, contribute unique expertise to team-based care, and help programmes expand access to care. The role of the clinical valve co-ordinator is unevenly adopted in Europe. Aims: To provide guidance on developing, implementing, and sustaining the role of clinical valve co-ordinators to support patients and programmes. Methods and results: We outline a comprehensive framework of the competencies and professional development aligned with the needs of patients with aortic, mitral, and tricuspid disease, discuss requirements for infrastructure and successful organizational integration in valvular heart disease teams and programmes, and propose preliminary indicators to measure role impact and address the current gap in evidence to guide role development across diverse regions. The clinical valve co-ordinator plays a vital role as a central member of the multidisciplinary team to support the care requirements of people with complex valvular heart disease in the rapidly evolving clinical context of treatment options and management strategies. Conclusion: The document provides a roadmap for the development, implementation, and evaluation of a pan-European initiative to improve the delivery of valvular heart disease services and optimize the experience of care of patients and their family.